On Nov 08, major Wall Street analysts update their ratings for $Moderna (MRNA.US)$, with price targets ranging from $55 to $111.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $70.
BofA Securities analyst Alec Stranahan maintains with a hold rating, and adjusts the target price from $110 to $90.
Barclays analyst Gena Wang maintains with a buy rating, and adjusts the target price from $125 to $111.
TD Cowen analyst Tyler Van Buren maintains with a hold rating, and adjusts the target price from $60 to $55.
Needham analyst Joseph Stringer maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Moderna (MRNA.US)$'s main analysts recently are as follows:
Moderna's Q3 SpikeVax revenue exceeded expectations, and the company has maintained its previously issued guidance. Despite this, a cautious outlook has been presented for 2025, which could be influenced by the anticipated approval of two additional vaccines.
Moderna's recent performance, which exceeded expectations in COVID vaccine sales, was partly due to the earlier commencement of the vaccination season compared to the previous year. Nevertheless, the company has adjusted its projection for vaccination rates for the year from initially expecting them to be consistent with last year's to now anticipating a possible decline of up to 10%. It was also mentioned that while the revenue forecast for the year has been maintained, the company anticipates results to be towards the lower end of the previously stated range.
Here are the latest investment ratings and price targets for $Moderna (MRNA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
